Review
[The possibility of S-1 for the treatment of patients with urological cancers]
[Article in
Japanese]
Affiliations
- PMID: 16898009
Item in Clipboard
Review
[The possibility of S-1 for the treatment of patients with urological cancers]
[Article in
Japanese]
Gan To Kagaku Ryoho.
2006 Jun.
Abstract
5-FU is a major anti-tumor agent, and many clinical trials have been conducted to determine the efficacy of 5-FU and fluoropyrimidine derivatives for the treatment of urological cancers. S-1 is an oral fluoropyrimidine derivative that should be tested to demonstrate clinical efficacy for the treatment of urological cancers. Two phase II trials are being conducted to evaluate the efficacy and safety of S-1 as a single agent therapy for patients with hormone-refractory prostate cancer (HRPC) and renal cell carcinoma (RCC).
Similar articles
-
Rapid development of S-1 in the west for therapy of advanced gastric carcinoma.Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:117-20. Gan To Kagaku Ryoho. 2006. PMID: 16897985 Review.
-
[Clinical efficacy of administration with S-1 alone for head and neck carcinoma].Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:144-9. Gan To Kagaku Ryoho. 2006. PMID: 16897991 Review. Japanese.
-
[Clinical benefit of S-1 in metastatic breast cancer].Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:202-6. Gan To Kagaku Ryoho. 2006. PMID: 16898003 Review. Japanese.
-
[S-1 for treatment of breast cancers].Nihon Rinsho. 2000 Apr;58 Suppl:284-91. Nihon Rinsho. 2000. PMID: 11026008 Review. Japanese. No abstract available.
-
[Two cases of advanced pancreatic cancer with cervical lymph node or liver metastasis responding well to S-1 monotherapy].Gan To Kagaku Ryoho. 2006 Oct;33(10):1505-9. Gan To Kagaku Ryoho. 2006. PMID: 17033248 Japanese.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources